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A 51-year-old man visited our hospital with a chief complaint of left renal mass detected by
ultrasonography in another hospital. Enhanced computed tomography (CT) revealed a hypovascular
tumor measuring about 9 cm in the left kidney, tumor thrombus in the inferior vena cava and paraaortic
lymph nodes metastases. Radical left transperitoneal nephrectomy with removal of the thrombus from the
left renal vein were performed. Paraaortic lymph nodes dissection was partially performed because of the
solid adhesion to aorta. Histological examination revealed collecting duct carcinoma (CDC). He was
treated with systemic chemotherapy (gemcitabine plus nedaplatin) followed by sunitinib. Duration of stable
disease after initiation of therapy was seventeen months, and survival after surgery was 31 months. It would
be worthwhile to prospectively evaluate the antitumor activity of tyrosine kinase inhibitors against metastatic
CDC.
(Hinyokika Kiyo 60 : 133-136, 2014)
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患 者 : 51歳，男性











初診時検査所見 : CRP 0.74 mg/dl，血清クレアチ




腹部ダイナミック CT : 左腎髄質より腎の概形を変
えず発達する造影効果の低い最大径 9 cm の腫瘍を認
め，内部に中心性壊死と思われる low density area を
伴っていた．また，腎静脈内に腫瘍塞栓を伴ってお
り，一部で下大静脈まで到達していた．また，腎門部
に多発する最大径 19 mm のリンパ節腫大を認めた
(Fig. 1）．
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Fig. 1. Enhanced CT scan shows the left renal tumor (9 cm in diameter) poorly enhanced,




Fig. 2. HE staining shows the papillary growth with ﬁbrous stroma of tumor cells (a) (×400). Immunohis-
tochemical staining shows PNA (b) and SBA (c) positive, and CD-10 (d) negative.














シタビン 1,500 mg/day 1 投与，ネダプラチン 75 mg/
day 1・8 投与）を 2 コース投与した．自験例では腎
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Fig. 3. The maximum size of the paraaortic lymph node (arrow) was 19 mm at the time of diagnosis (a), 20 mm at
the onset of treatment (b), and after that, no signiﬁcant increase in size was seen after 8 months (c), 15








通院可能な薬剤として スニチニブ37.5 mg/日を 4週
投与・2週休薬のスケジュールで開始した．治療開始
より17カ月（スニチニブ投与11コース終了後）までは
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Table 1. Therapeutic regimens against metastatic collecting duct carcinoma
報告者（報告年) N 治療レジメン 効果判定（期間 : 月) 生存期間（月)
Milowsky, et al（2002)7) 1 Paclitaxel＋Ifosfamide＋Cisplatin 1 PR (2) 10
Mejean, et al（2003)8) 2 Gemcitabine＋Cisplatin 2 CR (27, 9)
Oudard, et al（2007)2) 23 Gemcitabine＋Cisplatin or Carboplatin 1 CR, 5 PR, 10 SD 10.5（平均)
Staehler, et al（2008)3) 2 Gemcitabine＋Cisplatin followed by Sunitinib 2 PD 8
Ansari, et al（2009)4) 1 Sorafenib 1 PR (13)
Miyake, et al（2010)5) 1 Sunitinib 1 PR (7) 9
加藤ら（2010)9) 1 Gemcitabine＋Carboplatin 1 PR (4) 6
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